- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Lupin Limited — Updates, 08-04-2026: Press Release
08-04-2026 | 05:20 pm
08-04-2026 | 05:20 pm
Lupin received U.S. FDA approval for its generic Dapagliflozin & Metformin Hydrochloride Extended-Release Tablets across multiple dosages, plus tentative approval for another. This strategic move, bioequivalent to Xigduo® XR, expands Lupin's market presence in the US.
No comments yet. Be the first to comment!